Grafa News and Videos — Page 641

Danaher (NYSE:DHR), a global science and technology innovator, announced that it has completed the acquisition of Masimo (NASDAQ:MASI), a specialty diagnostics provider known for pulse oximetry and other patient monitoring solutions in acute care settings.

Prenetics Global (NASDAQ:PRE), the parent company of the IM8 premium health and longevity brand, reported first-quarter 2026 revenue of $36 million, with IM8 contributing $33.8 million.

HEICO (NYSE:HEI) announced that its Exxelia subsidiary has acquired a 90% stake in CalRamic Technologies, a Reno, Nevada-based manufacturer of high-voltage ceramic capacitors.

T. Rowe Price Group (NASDAQ:TROW) reported month-end assets under management (AUM) of $1.89 trillion as of May 31, 2026.

ParaZero Technologies (NASDAQ:PRZO) announced that it has secured two purchase orders in Israel for its DefendAir Net Pod system, marking a significant step in integrating its autonomous Counter-UAS technology into advanced defense platforms.

Paramount Skydance's (NASDAQ:PSKY) proposed $110 billion acquisition of Warner Bros. Discovery (NASDAQ:WBD) has come under formal scrutiny from the European Union over its financial backing from Middle Eastern sovereign wealth funds, according to a European Commission filing.

Figure Technology Solutions (NASDAQ:FIGR) announced a definitive agreement to acquire Kiavi, an AI-powered lending platform tailored for residential real estate investors, in a transaction valued at $717 million.

Scinai Immunotherapeutics (NASDAQ:SCNI) reported a net profit for the first quarter of fiscal year 2026, driven primarily by a substantial, non-cash accounting gain linked to its recent acquisition of Recipharm Israel.

Cullinan Therapeutics (NASDAQ:CGEM) reported encouraging initial clinical data and outlined expanded development pathways for its portfolio of dual-targeting T-cell engagers, marking an expansion for the oncology-focused biotech into the autoimmune space.

Artelo Biosciences (NASDAQ:ARTL) announced encouraging human metabolite identification and profiling data for its lead drug candidate, ART26.12, as the biotechnology company aims to de-risk the development of its novel non-opioid pain therapy.